CJC-1295 w/ DAC

Common questions about CJC-1295 w/ DAC

What is CJC-1295 with DAC?

CJC-1295 with DAC is a modified GHRH analog with a Drug Affinity Complex (DAC) linker. The DAC tag binds covalently to serum albumin, dramatically extending half-life and supporting sustained GH secretagogue activity.

Is CJC-1295 with DAC FDA-approved?

No. CJC-1295 with DAC is not approved by the FDA, MHRA, Health Canada, or the TGA for any indication. Research-peptide vendors sell it for laboratory research only.

What is the half-life of CJC-1295 with DAC?

The DAC linker extends the effective half-life to approximately 6–8 days through albumin binding, which is what differentiates the with-DAC variant from the no-DAC (Mod-GRF 1-29) form.

What dose of CJC-1295 with DAC is used in research?

Doses reported in published preclinical and early human pharmacokinetic studies vary by endpoint. Pepticker does not publish a dosing protocol — refer to the original literature for the specific study you are reproducing.

What is CJC-1295 with DAC commonly stacked with?

In published research and vendor protocols, CJC-1295 with DAC is most often paired with ipamorelin or another ghrelin-receptor agonist to combine sustained GHRH-arm activity with pulsatile ghrelin-arm activity.

How is CJC-1295 with DAC different from CJC-1295 without DAC?

The DAC linker is the only structural difference. With DAC, the peptide binds albumin and persists for days; without DAC (Mod-GRF 1-29), the half-life collapses to roughly 30 minutes, requiring much more frequent dosing for sustained GH elevation.

Editorial summary of published research. Not medical advice. See /methodology for sourcing.